GE HealthCare Technologies Inc. (NASDAQ: GEHC) announced a definitive agreement to acquire SOFIE Biosciences, a leading U.S.‑based contract manufacturing organization (CMO) for PET radiopharmaceuticals, from Trilantic North America for a cash purchase price of US$945 million. The transaction is expected to close in the first half of 2027, subject to regulatory approvals and customary closing conditions. Upon completion, SOFIE Biosciences will be integrated into GE HealthCare’s Pharmaceutical Diagnostics (PDx) segment, strengthening the company’s vertically integrated radiopharmaceutical supply chain and adding the Phase III F18 FAPI‑74 imaging asset — for which GE HealthCare already holds exclusive rights outside the United States.
Transaction Overview
| Item | Detail |
|---|---|
| Acquirer | GE HealthCare Technologies Inc. (NASDAQ: GEHC) |
| Target | SOFIE Biosciences (U.S.‑based PET radiopharmaceutical CMO) |
| Seller | Trilantic North America (private equity) |
| Purchase Price | US$945 million (all cash) |
| Consideration Form | 100% cash |
| Integration | SOFIE Biosciences to join GE HealthCare PDx segment |
| Expected Close | First half of 2027 |
| Conditions | Regulatory approvals and customary closing conditions |
| Announcement Date | 5 October 2026 |
Strategic Rationale & Asset Portfolio
SOFIE Biosciences – Core Capabilities
- PET Radiopharmaceutical CMO: SOFIE Biosciences is a leading U.S. contract manufacturer specializing in the production of PET (positron emission tomography) radiopharmaceuticals, with a highly skilled team and deep expertise serving U.S. customers.
- Flyrcado® Manufacturing Partner: SOFIE currently manufactures Flyrcado® (flurpiridaz F18 injection) — GE HealthCare’s proprietary F18‑labeled myocardial perfusion imaging agent — making the acquisition a vertical integration play that brings a critical manufacturing partner in‑house.
- Established U.S. Radiopharmacy Network: SOFIE’s U.S. manufacturing infrastructure and regulatory expertise provide GE HealthCare with enhanced domestic supply chain control for short‑half‑life radiopharmaceuticals, where proximity to clinical sites and reliable just‑in‑time delivery are mission‑critical.
FAPI‑74 – Phase III Pipeline Asset
| Item | Detail |
|---|---|
| Asset | FAPI‑74 — F18‑labeled Fibroblast Activation Protein Inhibitor (FAPI) |
| Development Stage | Phase III clinical trials |
| Mechanism | Targets fibroblast activation protein (FAP), a transmembrane protein overexpressed in the stroma of numerous solid tumors and fibrotic tissues |
| GE HealthCare Rights (Pre‑Acquisition) | Exclusive rights outside the United States |
| GE HealthCare Rights (Post‑Acquisition) | Full worldwide rights upon closing |
| Application | PET imaging of FAP‑expressing tumors — potential pan‑tumor diagnostic with applications across oncology indications |
FAPI‑74 represents a high‑value next‑generation radiopharmaceutical imaging agent with the potential to complement and expand GE HealthCare’s existing oncology imaging portfolio. FAP‑targeted PET imaging has emerged as a rapidly advancing field with demonstrated utility across a broad spectrum of solid tumors, including breast, lung, pancreatic, colorectal, and head and neck cancers.
Market Impact & Outlook
- Vertical Integration of Radiopharmaceutical Supply: The PET radiopharmaceutical market is uniquely constrained by the short half‑lives of F18 (~110 minutes) and other radioisotopes, making proximity of manufacturing to clinical sites a critical competitive advantage. Acquiring SOFIE gives GE HealthCare direct control over a key node in its U.S. radiopharmaceutical supply chain, reducing dependency on third‑party CMOs and improving reliability of supply for both existing products (Flyrcado®) and pipeline assets (FAPI‑74).
- Flyrcado® Supply Security: As the manufacturer of Flyrcado®, SOFIE’s integration eliminates a single‑vendor manufacturing risk for one of GE HealthCare’s flagship cardiology imaging products, ensuring uninterrupted supply as Flyrcado® scales commercially in the U.S. market.
- FAPI‑74 – Pan‑Tumor Imaging Potential: The acquisition of full global rights to FAPI‑74 transforms GE HealthCare’s position in the emerging FAP‑targeted imaging category. FAPI PET imaging has shown promise in detecting tumors that are poorly visualized by conventional FDG‑PET, potentially expanding the addressable imaging market. With Phase III data forthcoming, FAPI‑74 could become a significant commercial addition to GE HealthCare’s PDx portfolio.
- PDx Segment Growth Engine: The PDx segment — GE HealthCare’s pharmaceutical diagnostics division — is positioned as a high‑growth, high‑margin business within the broader GE HealthCare portfolio. The SOFIE acquisition accelerates PDx’s strategic evolution from a device‑centric imaging equipment company toward an integrated radiopharmaceutical platform with proprietary manufacturing, pipeline, and commercial infrastructure.
- Cash Deal at $945M – Disciplined Valuation: At US$945 million in cash, the acquisition represents a targeted, bolt‑on investment rather than a transformative M&A event. The all‑cash structure suggests confidence in near‑term value creation through operational integration and pipeline advancement, without dilution to GE HealthCare shareholders.
- Competitive Positioning: The deal strengthens GE HealthCare’s competitive moat against rivals including Siemens Healthineers, Philips, and emerging radiopharmaceutical‑focused companies (e.g., Lantheus, Radiopharm Theranostics) by consolidating both manufacturing capability and a Phase III pipeline asset in a single transaction.
- Theranostics Tailwind: FAPI‑74’s mechanism — targeting fibroblast activation protein — aligns with the rapidly growing theranostics paradigm, where the same molecular target is used for both diagnostic imaging and targeted radionuclide therapy. GE HealthCare’s acquisition of FAPI‑74 positions the company to potentially participate in the theranostics value chain as FAP‑targeted therapeutic candidates advance in parallel development programs across the industry.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding the expected closing of the acquisition, integration plans, regulatory approvals, clinical development of FAPI‑74, and commercial expectations for SOFIE Biosciences and GE HealthCare’s PDx segment. Actual results may differ materially due to risks including regulatory approval timelines, integration execution, Phase III clinical trial outcomes for FAPI‑74, competitive dynamics in the radiopharmaceutical market, manufacturing scale‑up, market access and reimbursement considerations, and general economic conditions. The transaction is subject to customary closing conditions and may not close on the anticipated timeline or at all. Investors are advised to exercise caution.-Fineline Info & Tech
